National City, California 91950

  • positive Bacterial


Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 (Telavancin) can control infections and whether the drug is safe to give to patients.


Inclusion Criteria: - Patients must have a diagnosis of one of the following complicated skin and soft tissue infections and either a suspected or confirmed Gram positive organism - major abscess requiring surgical incision and drainage - infected burn (see exclusion criteria for important qualifications) - deep/extensive cellulitis - infected ulcer (see exclusion criteria for important qualifications) - wound infection - Patients must be expected to require at least 4 days of intravenous (IV) antibiotic treatment Exclusion Criteria: - Previous systemic antibacterial therapy (with the exception of aztreonam and metronidazole) for > 24 hours within 7 days prior to the first dose of study drug unless the pathogen was resistant to prior treatment or the patient was a treatment failure (no clinical improvement after 3 days) - Burns involving > 20% of body surface area or third degree/full thickness in nature, diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fasciitis, gas gangrene, or mediastinitis



Primary Contact:

Principal Investigator
G. Ralph Corey, MD
Duke University

Backup Contact:


Location Contact:

National City, California 91950
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.